On July 10, the Trump Administration announced that it would withdraw a proposed rule to eliminate the safe harbor in the federal anti-kickback law for rebates negotiated by pharmacy benefit managers (PBMs) on behalf of Medicaid managed care plans and Medicare Part D plans. This is a highly welcome move. As we have explained since […]
As I have previously warned, the ongoing prescription drug pricing debate could intentionally or unintentionally lead to significant harm to the Medicaid program and its effective Drug Rebate Program. That, in turn, could result in higher federal and state Medicaid drug costs and reduced beneficiary access to needed medications. One key element of the Medicaid […]
We submitted comments to the Trump Administration’s proposed regulation to eliminate the safe harbor in the federal anti-kickback law for rebates negotiated by pharmacy benefit managers (PBMs) on behalf of Medicaid managed care plans (and Medicare Part D plans). As we have previously written, the proposed regulation raises serious concerns because it would likely […]
On March 11, the Trump Administration released its fiscal year 2020 budget. As my colleague Andy Schneider has written, the Administration budget plan would repeal the Affordable Care Act’s Medicaid expansion, impose a per capita cap or block grant on the rest of the Medicaid program, require all states to adopt onerous work reporting requirements […]
As federal efforts to address prescription drug costs intensifies, this three-part blog series addresses misleading claims or confusion about Medicaid, its highly effective drug rebate program and overall drug pricing issues in the hopes of better informing the debate moving forward. Part I | Part II Medicaid’s best price requirement is not the reason why […]
As federal efforts to address prescription drug costs intensifies, this three-part blog series addresses misleading claims or confusion about Medicaid, its highly effective drug rebate program and overall drug pricing issues in the hopes of better informing the debate moving forward. Part I | Part III Aggressive negotiation and closed formularies are only one factor in […]
